NSRX Nasus Pharma Ltd

Fundamentals / CIK 0002029039 / USD

Nasus Pharma Ltd reported $1.24B in revenue and a net loss of $5.86M for the fiscal year ended December 31, 2025, with a -0.4% operating margin.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open NSRX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

3 fiscal years (2023 to 2025), reported in USD.

$1.22B$608.9M$0-$110.5MFY 2023 Net Income: -$1.05M2023FY 2024 Net Income: -$1.53M2024FY 2025 Revenue: $1.24BFY 2025 Net Income: -$5.86M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31
Revenue $1.24B -- --
Research & Development $2.24M $335K $567K
Total Operating Expenses $4.90M $1.08M $1.15M
Operating Income -$4.90M -$1.08M -$1.15M
Interest Expense -$78K $29K $49K
Net Income -$5.86M -$1.53M -$1.05M
Basic EPS -$0.72 -$0.22 -$0.15
Diluted EPS -$0.72 -$0.22 -$0.20
Basic Shares Outstanding 8.0M 7.0M 6.9M
Diluted Shares Outstanding 8.0M 7.0M 7.1M

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

No quarterly income statement rows are available in SEC EDGAR CompanyFacts for NSRX.

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31
Cash & Cash Equivalents $1.24M $284K
Cash & Short-Term Investments $1.24M $284K
Other Current Assets $186K $29K
Total Current Assets $4.86M $457K
Property, Plant & Equipment, Net $14K --
Total Non-Current Assets $149K $260K
Total Assets $5.00M $717K
Accounts Payable $829K $651K
Total Current Liabilities $2.16M $3.93M
Total Non-Current Liabilities $73K $0
Total Liabilities $2.24M $3.93M
Total Debt (incl. Leases) $118K --
Common Stock -- $20K
Retained Earnings -$18.52M -$12.66M
Total Stockholders' Equity $2.77M -$3.21M
Total Equity $2.77M -$3.21M

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2025-12-31 2024-12-31
Cash & Cash Equivalents $1.24M $284K
Cash & Short-Term Investments $1.24M $284K
Other Current Assets $186K $29K
Total Current Assets $4.86M $457K
Property, Plant & Equipment, Net $14K --
Total Non-Current Assets $149K $260K
Total Assets $5.00M $717K
Accounts Payable $829K $651K
Total Current Liabilities $2.16M $3.93M
Total Non-Current Liabilities $73K $0
Total Liabilities $2.24M $3.93M
Total Debt (incl. Leases) $118K --
Common Stock -- $20K
Retained Earnings -$18.52M -$12.66M
Total Stockholders' Equity $2.77M -$3.21M
Total Equity $2.77M -$3.21M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31
Net Income -$5.86M -$1.53M -$1.05M
Stock-Based Compensation $447K $10K $39K
Change in Payables $152K -$5.0K -$116K
Operating Cash Flow -$4.92M -$665K -$1.03M
Capital Expenditure -$14K -- --
Free Cash Flow -$4.93M -- --
Investing Cash Flow -$3.01M -- --
Common Stock Issued $8.48M -- --
Financing Cash Flow $8.92M $770K $1.05M
Net Change in Cash $980K $101K $39K

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

No quarterly cash flow statement rows are available in SEC EDGAR CompanyFacts for NSRX.

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31
Operating Margin -0.4% -- --
Net Profit Margin -0.5% -- --
Return on Equity (ROE) -211.6% -- --
Return on Assets (ROA) -117.0% -213.7% --
Current Ratio 2.24x 0.12x --
Quick Ratio 0.57x 0.07x --
Debt to Equity 0.04x -- --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

No quarterly ratios & growth rows are available in SEC EDGAR CompanyFacts for NSRX.
Source: SEC EDGAR CompanyFacts (CIK 0002029039) · from December 31, 2023 Data through December 31, 2025 · synced Nov 21, 2026, 05:02 UTC · Open in terminal